Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration
Copyright 2008 S. Karger AG, Basel..
BACKGROUND: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD).
METHOD: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone). All patients were consecutively included, in the first phase of the study for triamcinolone, and in the second phase of the study for bevacizumab. The mean follow-up was 8.5+/-6.8 months (2-35.7 months).
RESULTS: In the bevacizumab group, best visual acuity increased significantly (p<0.001) by 3.2+/-3.4 Snellen lines, with 25 (69%) eyes and 21 (58%) eyes, improving by at least 2 and 3 Snellen lines, respectively. In the triamcinolone group, the visual acuity change was not statistically significant for any specific follow-up examination within the first 3 months. The maximal increase in visual acuity, the visual acuity change at 2 months after injection and the percentage of patients with an improvement by at least 2 and 3 Snellen lines were significantly (p<0.001) higher in the bevacizumab group than in the triamcinolone group. Intraocular pressure increased significantly (p<0.001) in the triamcinolone group and did not change significantly (p=0.47) in the bevacizumab group.
CONCLUSION: In exudative AMD, intravitreal bevacizumab (1.5 mg) compared with intravitreal triamcinolone acetonide (about 20 mg) results in a higher improvement of visual acuity and does not markedly influence intraocular pressure within 2 months after injection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Ophthalmic research - 41(2009), 1 vom: 01., Seite 21-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jonas, Jost B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2009 Date Revised 19.11.2015 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000162113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM182970086 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM182970086 | ||
| 003 | DE-627 | ||
| 005 | 20231223163754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000162113 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0610.xml |
| 035 | |a (DE-627)NLM182970086 | ||
| 035 | |a (NLM)18849638 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jonas, Jost B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2009 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2008 S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND: To compare an intravitreal high-dose injection of triamcinolone acetonide with an intravitreal injection of bevacizumab for the treatment of progressive exudative age-related macular degeneration (AMD) | ||
| 520 | |a METHOD: The comparative nonrandomized retrospective clinical interventional study included 305 patients with progressive AMD, divided into a bevacizumab group of 36 patients (1.5 mg bevacizumab) and a triamcinolone group of 269 patients (about 20 mg triamcinolone). All patients were consecutively included, in the first phase of the study for triamcinolone, and in the second phase of the study for bevacizumab. The mean follow-up was 8.5+/-6.8 months (2-35.7 months) | ||
| 520 | |a RESULTS: In the bevacizumab group, best visual acuity increased significantly (p<0.001) by 3.2+/-3.4 Snellen lines, with 25 (69%) eyes and 21 (58%) eyes, improving by at least 2 and 3 Snellen lines, respectively. In the triamcinolone group, the visual acuity change was not statistically significant for any specific follow-up examination within the first 3 months. The maximal increase in visual acuity, the visual acuity change at 2 months after injection and the percentage of patients with an improvement by at least 2 and 3 Snellen lines were significantly (p<0.001) higher in the bevacizumab group than in the triamcinolone group. Intraocular pressure increased significantly (p<0.001) in the triamcinolone group and did not change significantly (p=0.47) in the bevacizumab group | ||
| 520 | |a CONCLUSION: In exudative AMD, intravitreal bevacizumab (1.5 mg) compared with intravitreal triamcinolone acetonide (about 20 mg) results in a higher improvement of visual acuity and does not markedly influence intraocular pressure within 2 months after injection | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Triamcinolone Acetonide |2 NLM | |
| 650 | 7 | |a F446C597KA |2 NLM | |
| 700 | 1 | |a Ihloff, Anna K |e verfasserin |4 aut | |
| 700 | 1 | |a Harder, Bjoern |e verfasserin |4 aut | |
| 700 | 1 | |a Kreissig, Ingrid |e verfasserin |4 aut | |
| 700 | 1 | |a Schlichtenbrede, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Libondi, Teodosio |e verfasserin |4 aut | |
| 700 | 1 | |a Spandau, Ulrich H M |e verfasserin |4 aut | |
| 700 | 1 | |a Vossmerbaeumer, Urs |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ophthalmic research |d 1982 |g 41(2009), 1 vom: 01., Seite 21-7 |w (DE-627)NLM012595640 |x 1423-0259 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2009 |g number:1 |g day:01 |g pages:21-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000162113 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2009 |e 1 |b 01 |h 21-7 | ||